Article Figures & Data
Figures
- Fig 1.
A 58-year-old woman with metastasis from melanoma undergoing MR imaging for definite staging of metastatic disease. T1 SE (A and B) and T1 GRE (C and D) images reveal a metastasis in the right superior frontal gyrus. However, the lesion appears larger and shows more conspicuous enhancement with gadobenate dimeglumine (A and C) than with gadobutrol (B and D).
- Fig 2.
A 70-year-old man with metastasis from lung carcinoma undergoing MR imaging for identification and location of metastatic disease. T1 SE (A and B) and T1 GRE (C and D) images reveal a large metastasis in the posterior aspect of the left cerebellar hemisphere. The lesion appears larger, shows more conspicuous enhancement, and is better demarcated with gadobenate dimeglumine (A and C) than with gadobutrol (B and D).
- Fig 3.
A 49-year-old woman with juxta-/prerolandic right frontal glioma undergoing MR imaging for assessment of tumor evolution. T1 SE (A and B) and T1 GRE (C and D) images reveal a large inhomogeneous tumor. The presence of a small enhancing focus (arrow) in the ventral portion of the tumor is seen clearly only on gadobenate dimeglumine–enhanced images (A and C). The enhancing area is nearly undetectable on gadobutrol-enhanced images (B and D).
- Fig 4.
Blinded reader comparison of CNR (A) and LBR (B) after 0.1-mmol/kg doses of gadobenate dimeglumine and gadobutrol. Highly significant increases in quantitative enhancement for gadobenate dimeglumine are noted by all 3 readers for both CNR (P < .02) and LBR (P < .0001).
Tables
Diagnostic Information End Point Reader Gadobenate Dimeglumine Preferred Gadobutrol Preferred Significance (P Value) 3-Reader Agreement (κ value) Global diagnostic preference 1 46 (40.7%) 6 (5.3%) <.0001 0.524 (61.9%) 2 54 (47.4%) 7 (6.1%) <.0001 3 49 (53.2%) 7 (6.1%) <.0001 Lesion border delineation 1 43 (38.1%) 5 (4.4%) <.0001 0.544 (66.4%) 2 39 (34.2%) 3 (2.6%) <.0001 3 37 (34.0%) 3 (2.6%) <.0001 Definition of disease extent 1 18 (15.9%) 1 (0.9%) <.0001 0.414 (73.5%) 2 21 (18.4%) 3 (2.6%) <.0001 3 20 (17.5%) 0 <.0001 Visualization of lesion internal morphology 1 39 (34.5%) 5 (4.4%) <.0001 0.629 (73.5%) 2 35 (30.7%) 4 (3.5%) <.0001 3 36 (31.6%) 1 (0.9%) <.0001 Lesion contrast enhancement 1 53 (46.9%) 7 (6.2%) <.0001 0.547 (62.8%) 2 62 (54.4%) 10 (8.8%) <.0001 3 50 (43.9%) 7 (6.1%) <.0001 -
↵a Comparisons based on 113 patients for reader 1 and 114 patients for readers 2 and 3. All other comparisons were considered equal. Numbers in parentheses represent proportions of patients.
-
Specifications of Global Diagnostic Preference Preference Expressed Reader 1 (n = 52) Reader 2 (n = 61) Reader 3 (n = 56) Gadobenate Dimeglumine (n = 46) Gadobutrol (n = 6) Gadobenate Dimeglumine (n = 54) Gadobutrol (n = 7) Gadobenate Dimeglumine (n = 49) Gadobutrol (n = 7) Superior contrast enhancement 34 (73.9%) 4 (66.7%) 53 (98.1%) 7 (100%) 47 (95.9%) 7 (100%) Better delineation of normal structures 0 0 1 (1.9%) 0 1 (2.0%) 0 Better delineation of at least 1 lesion 28 (60.9%) 4 (66.7%) 21 (38.9%) 0 17 (34.7%) 1 (14.3%) Better visualization of lesion internal structure 14 (30.4%) 4 (66.7%) 16 (29.6%) 3 (42.9%) 9 (18.4%) 0 Detection of more lesions 2 (4.3%) 0 1 (1.9%) 1 (14.3%) 3 (6.1%) 0 Greater diagnostic confidence 2 (4.3%) 0 2 (3.7%) 0 3 (6.1%) 0
In this issue
Jump to section
Related Articles
Cited By...
- Comparative Evaluation of Lower Gadolinium Doses for MR Imaging of Meningiomas: How Low Can We Go?
- Reply:
- The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)
- Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study)
- Gadolinium Contrast Agents for CNS Imaging: Current Concepts and Clinical Evidence
- Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)